Suppr超能文献

[接受全身溶栓治疗患者中肌酸激酶同工酶MB动力学的评估]

[Evaluation of the kinetics of MB creatine kinase in patients undergoing systemic thrombolytic therapy].

作者信息

Arrigo F, Saccà C M, Cavalli A, Egitto M, Barillari M, Costa G, Cavalli G, Carerj S, Melluso C

机构信息

Istituto Pluridisciplinare di Clinica e Terapia Medica I, Università degli Studi, Messina.

出版信息

Cardiologia. 1991 Nov;36(11):861-6.

PMID:1817758
Abstract

This study was aimed to evaluate if the time-course of creatinkinase MB in acute myocardial infarction (AMI) is influenced by therapy and which index, derived from the enzymatic curve, is the most reliable marker of successful coronary artery recanalization. We studied the enzymatic curves in 38 patients with transmural myocardial infarction, 19 treated with streptokinase (SK) and 19 with tissue plasminogen activator (rtPA). Blood samples were obtained every 2 hours for the first 12 hours and every 6 hours until the level of serum CK returned to baseline. Three indexes were calculated: peak serum enzyme level, time to peak enzyme level and maximal enzyme rise velocity. Time to peak did not differ significantly between SK and rtPA groups. Peak levels were significantly higher (414 +/- 40 vs 249 +/- 33; p = 0.004) in rtPA groups, as well as maximal enzyme rise velocity (1.7 +/- 0.4 vs 0.8 +/- 0.1; p = 0.02). However, infarct size evaluated by the total release of CK-MB in 28 patients was greater in rtPA group (10949 +/- 1097 vs 6346 +/- 869; p = 0.002). These findings suggest that differences in peak level and in maximal velocity of rise observed between SK and rtPA are due to differences in infarct size and not to a different recanalization rate. Thus, enzymatic estimate of infarct size significantly correlates to peak enzyme (r = 0.894, p less than 0.001), and to maximal rise velocity (r = 0.518, p = 0.007) but not to time to peak (r = 0.208, NS).(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

本研究旨在评估急性心肌梗死(AMI)中肌酸激酶MB的时间进程是否受治疗影响,以及从酶曲线得出的哪个指标是冠状动脉再通成功的最可靠标志物。我们研究了38例透壁性心肌梗死患者的酶曲线,其中19例接受链激酶(SK)治疗,19例接受组织型纤溶酶原激活剂(rtPA)治疗。在最初12小时内每2小时采集一次血样,之后每6小时采集一次,直至血清肌酸激酶水平恢复至基线。计算了三个指标:血清酶峰值水平、达到酶峰值水平的时间和最大酶上升速度。SK组和rtPA组达到峰值的时间无显著差异。rtPA组的峰值水平显著更高(414±40对249±33;p = 0.004),最大酶上升速度也是如此(1.7±0.4对0.8±0.1;p = 0.02)。然而,通过28例患者中CK-MB的总释放量评估的梗死面积在rtPA组更大(10949±1097对6346±869;p = 0.002)。这些发现表明,SK和rtPA之间观察到的峰值水平和最大上升速度的差异是由于梗死面积的差异,而非再通率不同。因此,梗死面积的酶学估计与酶峰值显著相关(r = 0.894,p<0.001),与最大上升速度相关(r = 0.518,p = 0.007),但与达到峰值的时间无关(r = 0.208,无显著性差异)。(摘要截取自250字)

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验